Panobinostat (LBH589) is a novel pan-deacetylase inhibitor that is currently being evaluated in phase III clinical trials for treatment of Hodgkin's lymphoma and multiple myeloma. Under catalysis of recombinant human CYP3A4 and CYP2D6 coexpressed with human cytochrome P450 reductase in Escherichia coli JM109, five metabolites of panobinostat were produced via whole-cell biotransformation. The structures of the metabolites were elucidated with the spectroscopic methods mass spectrometry (MS) and NMR and revealed an oxidative cyclization of the ethyl-amino group to the methylindole moiety. The MS 2 spectrum of the cyclized metabolite showed a base peak, where the closed ring is reopened and that, taken as sole base for structure proposals, would have lead to wrong conclusions. The metabolites were substantially less potent deacetylase inhibitors than the parent compound.
Introduction
Histone deacetylases (HDACs) are a class of enzymes that remove acetyl groups from an -N-acetyl-lysine and thereby increase the ability of histones to bind to DNA. In healthy cells, there is a balance between activities of histone deacetylases and histone acetylases regulating the transcriptional activity. There is in vitro evidence in malignant cells that increased HDAC activity leads to prolonged survival through various mechanisms, such as disruption of cell-cycle regulation or of apoptosis (Marks et al., 2000; Lee et al., 2008) . Therefore, inhibition of HDAC is beneficial for treatment of cancer, and, currently, two HDAC inhibitors are approved by the U.S. Food and Drug Administration against cutaneous T-cell lymphoma, a rare form of non-Hodgkin's lymphoma: Vorinostat (Zolinza) and the natural product and cyclodepsipeptide romidepsin (Istodax; Zain et al., 2010) . Recent evidence shows that deacetylases also regulate diverse nonhistone proteins, such as P53 or HSP90, and it is therefore more appropriate to speak about deacetylase inhibitors rather than histone deacetylase inhibitors (Bolden et al., 2006) . Pan-deacetylase inhibitors that inhibit both HDAC and nonhistone targets have the potential to be applicable in the clinic to a wider set of tumor types. HDACs are divided into four classes: the zinc-dependent classes I, IIa, IIb, and IV and the NAD-dependent class III.
Panobinostat (LBH589) is an orally active pan-deacetylase inhibitor that inhibits in vitro class I, II, and IV HDAC with IC 50 in a low nanomolar concentration (Atadja, 2009) . It is currently being evaluated in phase III clinical trials for treatment of Hodgkin lymphoma and multiple myeloma (Prince et al., 2009) . Its structure features a hydroxamic acid and a 2-methylindole moiety linked with cinnamic acid and an aliphatic secondary amine.
Preclinical drug metabolism and pharmacokinetics results of the drug candidate will be published in due time, and a manuscript about the human metabolic pathways of panobinostat is in preparation (S. Clive, M. M. Woo, M. Stewart, T. Nydam, L. Kelly, P. Squier, and M. Kagan, manuscript in preparation) . In vivo studies with rats revealed a systemic metabolite that had a significantly later maximum of concentration (T max ) than the one of the parent compound panobinostat after oral administration, suggesting a slow elimination or, less likely, a delayed formation (M. Kagan, personal communication). The accurate mass suggested the same elemental composition as the parent panobinostat, and smaller MS/MS fragments suggested an oxygenated amide. However, it was not possible to find a meaningful explanation of the base peak in its MS/MS spectrum. These findings and the start of a back-up chemistry program in research, where all potential liabilities should be addressed, prompted the desire for an unambiguous structure elucidation of the aforementioned metabolite.
To assess drug metabolism and pharmacokinetics results, it is highly advantageous to elucidate the structure of critical or unusual metabolites by 1 H-and 13 C-NMR and to evaluate their biological activity. Whole-cell biotransformation is the method of choice to produce the milligram quantities necessary for such tasks (Schroer et al., 2010) . Thanks to an academia-industry collaboration between the Biomedical Research Centre of the University of Dundee, Scotland, and nine pharmaceutical companies (LINK I consortium), 14 different recombinant human (rh) P450s functionally coexpressed with rh P450-reductase in Escherichia coli are available (Blake et al., 1996; Pritchard et al., 1997 Pritchard et al., , 1998 .
In the present study, rh P450 CYP3A4 and CYP2D6 were used to prepare milligram amounts of oxidative metabolites of panobinostat for unambiguous structure elucidation and testing for their in vitro biological activity.
Materials and Methods
General. The following NMR instruments were used: a Bruker DRX500 spectrometer (Bruker BioSpin, Fällanden, Switzerland) , equipped with a 5-mm TXI-cryoprobe (triple resonance, heteronuclei inverse detected); a Bruker AV600, equipped with a 1.7-mm TXI-cryoprobe; or a Bruker DPX400 spectrometer with a 5-mm BBI (broad band resonance, heteronuclei inverse detected) probe. The compounds were dissolved in DMSO-d 6 in a 5-mm or 1.7-mm-diameter NMR tube. All spectra were recorded at 298 K. From M4 and M8 1 H, COSY, ROESY (rotational frame nuclear Overhauser effect spectroscopy), HSQC, and heteronuclear multiple-bond correlation spectroscopy (HMBC) spectra were accumulated, using a 1.7-mm TXI-cryoprobe at 600 MHz, in the case of M8 with only approximately 30 g.
The liquid chromatograph consisted of a UPLC Acquity (Waters, Milford, MA) equipped with a Waters Acquity PDA detector. Parameters were as follows: column, HSS T3 C18, 1.7 m, 1.0 ϫ 150 mm (Waters); flow rate, 0.1 ml/min.; eluent A, H 2 O/trifluoroacetic acid 100, 0.02; eluent B, ACN/ trifluoroacetic acid 100, 0.02; gradient: 0 min, 2% B; 15 min, 30% B; 17-18 min, 95% B; column temperature, 40°C; UV detection, 200 -330 nm; resolution, 2.4 nm; injection volume, 3 l.
An ion trap mass spectrometer (LTQ Velos; Thermo Fisher Scientific, Waltham, MA) equipped with a heated electrospray interface was operated in the positive mode with Xcalibur software version 2.1 as follows. A sheath gas setting of 20 units and auxiliary gas of 3 units were used, and a spray voltage of 3.5 kV was applied. The heated metal capillary was maintained at 300°C, with a mass range of 200 to 400 Da. The system was optimized for m/z 549 [M ϩ H] ϩ of antimycin A 1 in the positive mode. Typical parameters were as follows: S-Lens, 62%; multipole 00 offset, 4 V; gate lens, Ϫ35 V; front lens, Ϫ5.25 V. MS/MS parameters were as follows: isolation width, 2.4 Da; without wide-band excitation activated; normalized collision energy, 35%; activation time, 10 ms. Alternatively, a TSQ Quantum AM (Thermo Fisher Scientific) mass spectrometer equipped with an electrospray interface in the positive mode was used and operated with Xcalibur software version 2.0. A sheath gas setting of 20 units and auxiliary gas of 5 units were used, and a spray voltage of 3 kV was applied. The heated metal capillary was maintained at 280°C, with a mass range of 100 to 1000 Da. MS/MS parameters were as follows: collision gas, 1.5 mTorr argon; collision energy, 17 V.
For accurate mass measurements, an Orbitrap (Thermo Fisher Scientific) equipped with an electrospray interface was operated in the positive mode at high-resolution mode (30,000 Da). A sheath gas setting of 15 units and auxiliary gas of 1 unit were used, and a spray voltage of 4 kV was applied. The heated metal capillary was maintained at 275°C. Typical parameters were as follows: tube lens, 80 V; multipole 00 offset, Ϫ5 V; gate lens, Ϫ80 V; front lens, Ϫ6.5 V. MS/MS parameters were as follows: isolation width, 2.0 Da; normalized collision energy, 25%; activation time, 30 ms. Data acquisition and evaluation were done with Xcalibur 2.0.7 SP1.
Luria-Bertani broth (Miller's modification, L3397), antifoam 204, and isocitric dehydrogenase (from porcine heart, type IV) were purchased from SigmaAldrich (St. Louis, MO); LB agar (Vegitone; BioChemica 19344) was from Fluka (Buchs, Switzerland); Amberlite XAD16 (industrial grade) was from Rohm and Haas (Dow Chemical Company, Frankfurt, Germany); peptone from casein (pancreatic 1.02239) and yeast extract (1.03753), both for microbiology, were from Merck (Darmstadt, Germany); and Supersomes were from Becton Dickinson AG (Allschwil, Switzerland). Panobinostat and synthetic standards of metabolite M5 were obtained from Novartis (Basel, Switzerland).
Solutions and Growth Medium. The PSE buffer (50 mM KH 2 PO 4 , 250 mM sucrose, 0.25 mM EDTA-Na 2 ⅐H 2 O) was adjusted with 2N NaOH to pH 7.4. Stock solution of ampicillin (100 mg/ml in deionized water), chloramphenicol (25 mg/ml in ethanol), thiamine hydrochloride (1 M in deionized water), ␦-aminolevulinic acid (83.8 mg/ml in deionized water), or isopropyl ␤-Dthiogalactopyranoside (1 M in deionized water) were sterile filtered into aliquots and stored at Ϫ20°C. To make 200 ml of the trace element solution, first the iron(III) citrate (1.22 g) was added to 100 ml of water and stirred over heat until dissolved. After cooling, concentrated HCl (37%; 5 ml) was added to the solution, and the solution turned to a straw-yellow color. H 3 BO 3 ) was added to the solution, which was finally made up to 200 ml with water, sterile filtered, and stored at room temperature. All media for the cultivation of E. coli expressing CYP3A4 contained 100 g/ml ampicillin, and those for expressing CYP2D6 contained 100 g/ml ampicillin plus 25 g/ml chloramphenicol. Immediately before inoculation, liquid media were spiked with 1 ml/l each of the relevant antibiotic stock solution(s). To the agar medium, the antibiotic stock solution(s) was added after cooling to 50°C, just before pouring them into the Petri dishes. LB broth and LB agar were dissolved in deionized water, and the pH was adjusted to 7.2 and autoclaved at 121°C for 20 min.
For the 25-liter main culture, modified terrific broth was used as follows. Peptone (300 g) and yeast extract (600 g), the latter together with 25 ml of trace element solution, were each dissolved in 2 liters of water containing 1 ml of antifoam 204 agent. After adjusting the pH to 6.8 and autoclaving at 121°C for 20 min, the solutions were pumped into a sterile 50-liter polyethylene bag used for cultivation (Biostat Cultibag RM 50; Sartorius Stedim Systems GmbH, Guxhagen, Germany) under sterile conditions using a peristaltic pump. A second solution was prepared by dissolving K 2 HPO 4 (235 g), KH 2 PO 4 (55 g), glycerol (250 g), ampicillin stock solution (25 ml), and thiamine stock solution (25 ml) in 5 liters of water and, after adjusting the pH to 6.8, it was pumped into the wave bag through a sterile filter capsule-type Sartobran 150 containing two sequential membranes, with pore diameters 0.45 and 0.2 m (5231307H4-00; Sartorius AG, Gö ttingen, Germany), using a peristaltic pump. Finally, the medium was completed by pumping in 16 liters of demineralized water through the sterile filter capsule used before.
Fermentative Production of E. coli Cells with CYP3A4 Activity. From frozen glycerol stocks (Ϫ80°C, see below) of E. coli JM109 coexpressing rh CYP3A4 and rh P450-reductase, some material was streaked onto a LB agar plate containing ampicillin. After incubation at 37°C for 16 h, single colonies were used to inoculate the preculture consisting of 400 ml of LB broth with pH 6.8 distributed into two 500-ml shake flasks containing ampicillin, as mentioned above. The preculture was placed in an orbital shaker set at 37°C and at a rate of 220 rpm until it reached an OD600 between 0.7 and 1. Then it was stored overnight in a refrigerator at ϩ4°C.
The main culture was performed in a BioWave 50SPS bioreactor. In this system, a disposable polyethylene bag, here with 50 liters of total volume and 25 liters of working volume, serves as the reactor which is rocked on a temperature-controlled table at 30°C. Oxygen is supplied via a stream of sterile air through the headspace of the bag. Under conditions recommended for the cultivation of E. coli (42 rocks per minute, 10.5°rocking angle) and an airflow of 0.5 l/min under supplementation of 10% (v/v) of pure oxygen, the CYP3A4 expressing an E. coli cell line provides cell densities (OD600, 14 -16) and CYP3A4 activities comparable to the ones obtained in shake flasks.
The main culture volume was 25 liters of modified terrific broth with ampicillin inoculated with 1% v/v of preculture. Induction was performed at an OD600 of 0.7 to 1 by the addition of 1 mM isopropyl ␤-D-SCHEME 1. Structure and atom numbering of panobinostat (LBH589) and CYP3A4 or CYP2D6 metabolites and putative epoxide intermediate. M3 and M6 are proposed structures. The structures represent the relative configuration at centers 2 and 3. The naming of the metabolites (M1…) is different from the one used internally in Novartis and therefore also from other publications on panobinostat metabolism. thiogalactopyranoside and 0.5 mM ␦-aminolevulinic acid. The total cultivation time was approximately 24 h. The cells were centrifuged at 5000 rpm and 4°C for 15 min using a GS-3 rotor in a RC-5B refrigerated superspeed centrifuge (Sorvall; Kendro Laboratory Products AG, Zü rich, Switzerland). The pellet was resuspended in one tenth of the original main culture volume using PSE buffer. The cells were sedimented by centrifugation and resuspended another two times. For adsorbing indole and other potential P450 inhibitors, 150 g of XAD16, regenerated with methanol and water before use, was added, and the suspension was stirred with an overhead stirrer in an ice bath at 0°C for 30 -60 min and kept there overnight. Before use as biocatalyst, the XAD16 resin was removed from the cell suspension by filtration over gauze.
Bioconversion on Preparative Scale and Purification. The preparative bioconversion was again performed applying the BioWave 50SPS bioreactor under the same incubation conditions as for the fermentation. The 10-fold concentrated cell suspension (2.5 liters) was pumped into the 50-liter wavebag and was supplemented with 100 ml of an EDTA solution (100 g/l, pH 7.5). After warming to 25°C, a solution of the lactate salt of panobinostat (205 mg) in 200 l of DMSO, mixed rigorously with 200 ml of a suspension (5% w/v) of highly dispersed silicon dioxide (113126; Merck) in water, was added. Because no difference in metabolite formation was observed between the samples taken after 90 and 210 min by HPLC, the reaction was stopped by the addition of 200 g of XAD16 adsorber resin. After 2 h, all metabolite had adsorbed (HPLC analysis), and the resin was recovered from the combined suspensions by filtering over gauze, followed by washing with 2 liters of water.
The suspended resin was extracted four times with methanol (1 liter) and 2-propanol (1 liter) at room temperature under gentle shaking for 0.5 to 1 h, followed by vacuum filtration through a glass fiber filter. The combined solvents were removed in vacuo, the residue was suspended in methanol and mixed with 15 g of diatom granulate (Isolute HM-N; Separtis AG, Grellingen, Switzerland), and by evaporating the solvent under reduced pressure, the substances to be separated were absorbed to the Isolute material. The compounds were separated on a Labochrom AMC glass column (28 ϫ 350 mm; Labomatic Instruments AG, Allschwill, Switzerland) filled with Lichroprep RP-18 (40 -63 m). For the first chromatographic run, the crude extract absorbed on Isolute was dry filled in a precolumn (20 ϫ 250 mm; Bü chi Labortechnik AG, Flawil, Switzerland), which was prefilled to 50% height with Lichroprep RP-18. The metabolites were purified in two consecutive runs, with each linear gradient from 3% mobile phase B to 30% B in 50 min with a 30 ml/min flow rate. The first run was under acidic conditions using 10 mM aqueous formic acid (A)/ ACN (B) as mobile phases, and the second runs (separate runs for all compounds) were with mobile phase A (5 mM aqueous ammonium formate/ammonia, pH 7.1) and mobile phase B (ACN). The solvents of the metabolite-containing fractions were removed in vacuo, and the residues were dried in high vacuum. A total of 5 mg of M1 and 12 mg of M2 were obtained. In the same way, using E. coli JM109 coexpressing rh CYP2D6 and rh P450 reductase, the metabolites M4 (268 mg) and M7 (22 mg) were produced, also with a biotransformation time of 210 min.
Analytical Bioconversion Experiments. Suspensions of E. coli cells expressing 14 different P450 isoenzymes were diluted with PSE buffer to constant wet biomass (100 mg/ml). These suspensions (0.5 ml) were mixed with 25 l of a DL-isocitrate solution (0.46 g of Na 3 C 6 H 5 O 7 /ml) and 10 l of a substrate stock solution (5 mg/ml in ACN/DMSO, 19:1) in 2-ml Eppendorf caps, closed with stoppers to ensure aeration (steristoppers 10; Herenz, Hamburg, Germany), and incubated at 30°C and 1100 rpm in a temperaturecontrolled Eppendorf mixer (Eppendorf-Vaudaux AG, Schönenbuch, Switzerland) for 0.5 or 1 h. The reactions were stopped by mixing with 0.5 ml of ACN/methanol (1:1) for 5 min and centrifuged in an Eppendorf 5424R centrifuge, and the supernatant was subjected to LC-MS analysis.
The reaction conditions for the incubation with Supersomes were HEPES (185 mM, pH 7.5), LBH589 (10 M; stock solution, 1 mM in ACN), MgCl 2 (6.65 mM, including the quantity from the NADPH regeneration system), NADP ϩ ⅐Na 2 (0.5 mM), DL-isocitrate ⅐ Na 3 (2.54 mM), isocitric dehydrogenase (5 l/ml), and total volume (1 ml), with incubation in an Eppendorf Thermomixer at 30°C without shaking. The reactions were started by the addition of the NADPH regeneration system in the form of a 20-fold concentrated stock solution [NADP ϩ ⅐Na 2 , MgCl 2 (58 mM), DL-isocitrate⅐Na 3 , isocitric dehydrogenase] and initial gentle vortexing. After incubation for 1 h, the assays were extracted by shaking in the presence of 1 volume of ACN for 10 min and centrifuged at 21,000g in an Eppendorf 5424R centrifuge for 3 min. The supernatants were subjected to LC-MS analytics.
Minipreparative Biotransformation and Micropreparative Isolation of M8. For small-scale isolation of metabolite M8, an incubation with CYP2D6 expressing E. coli cells was performed in the same way as in the analytical bioconversion experiments, but using eight 10-ml aliquots of cell suspensions with 200 g/l wet biomass in 100-ml Erlenmeyer flasks incubated at 30°C on an orbital shaker (220 rpm; 50 mm shaking amplitude) and applying citrate solution instead of isocitrate. The reaction was stopped after 30 min by the addition of an equal volume of ACN. Then it was centrifuged and concentrated in vacuo to a volume of approximately 10 ml at 40°C using a Cyclone high-speed evaporator (Prolab Instruments GmbH, Reinach, Switzerland), yielding in average 5% of M8.
The residue was diluted with an equal volume of water and centrifuged at 4000g for 20 min in an Eppendorf centrifuge 5810R. Solid-phase extraction was performed with Plexa 200 mg/6 cc cartridges (Varian Inc., Palo Alto, CA) preconditioned with 3 ml of MeOH and conditioned with 3 ml of H 2 O. Aliquots of 10-ml samples were applied to the cartridges, which were washed twice with 3 ml of H 2 O/MeOH 95:5 (v/v). The product mixture was eluted with 3 ml of ACN, pooled, evaporated to dryness with the Cyclone high-speed evaporator, and reconstituted in 1.2 ml of H 2 O/ ACN 90:10 (v/v) for micropreparative isolation of M8. The micropreparative HPLC/MS system consisted of a Prominence UFLC system (SIL-20AC autosampler, LC-20AB pumping system, DGU-20A online solvent degasser, CBM-20A system controller; Shimadzu, Kyoto, Japan) with a column heater (Portmann, Biel, Switzerland) using the following LC conditions: Column XBridge BEH130 C18, 3.5 m, 4.6 ϫ 150 mm (Waters); mobile phase A, H 2 O ϩ 0.1% HCOOH; mobile phase B, ACN ϩ 0.1% HCOOH; gradient: 0 min, 5% B; 2 min, 5% B; 13 min, 35% B; 15 to 18 min, 95% B; 30°C; 0.5 ml/min; injection volume, 100 l. The chromatographic flow was split with a static T-union. The major portion (95%) was directed to a valve-switching system composed of a Cheminert six-port biposition divert valve (VICI AG International, Schenkon, Switzerland) used for fraction collection. The minor part of the chromatographic flow (5%) was introduced directly into the ion source of an ion trap mass spectrometer (LTQ XL; Thermo Fisher Scientific) equipped with a heated electrospray interface operating in the positive ion mode as follows: sheath gas/auxiliary gas/sweep gas, 10: HDAC Inhibition. The in vitro assay was performed as described by Sambucetti et al. (1999) and modified for isoform selectivity. With the exception of HDAC4, which was purchased from BPS Bioscience (San Diego CA), the isoenzymes were prepared in house: HDAC1, HDAC3, and HDAC6 were expressed in HEK-293, flag-tagged, HDAC2 in SF21, his-strep-tagged, and HDAC8 in SF9, tag cleaved.
Results
Occasionally, P450 enzymes, which are of low abundance in the liver or not present in this organ at all (e.g., CYP1A1), are the most efficient biocatalysts for drug metabolite synthesis (Schroer et al., ). Therefore, all 14 different rh P450s functionally coexpressed with rh P450-reductase in E. coli were screened for metabolite production on an analytical scale (whole-cell biotransformations) and investigated by LC-MS/MS (Table 1 ). The UV curve at 280 nm was used for a first quantification, because no standard compounds were available at that time. UV detection is commonly used in early metabolism, because the response factors of metabolites are mostly similar to the parent compound (Ramanathan et al., 2010) . Panobinostat reacted in high yields with the host strain JM109 and even in higher yields with some P450s. After prolonged exposure, as typically used for preparative conversion, a complete conversion of panobinostat to metabolites was observed. To differentiate between the host and P450 reactions, short reaction times were applied for the analytical experiment. Metabolites were identified by similar UV spectra, appropriate mass difference to the parent compound, and related MS/MS spectra.
A total of eight major metabolites was found by LC-MS/MS (Scheme 1), three of which were produced by the host as well. Hence, the host E. coli strain JM109 performed two reactions and the combination of these two: the faster reaction was the reduction of the hydroxamic acid to the amide forming M4 from LBH589, as well as M2 starting from M1. The considerably slower reaction in the host was the ring closure forming M1 from LBH589 or M2 from M4. This ring closure reaction yielding M1 and M2 ran at a higher rate in several P450s, notably CYP2A6, CYP3A4, and CYP3A5. The enzymes responsible for the E. coli host reactions are unknown, the more since native E. coli carries no P450s (Kelly et al., 2003) . The enzyme CYP2D6, and to a lower extent CYP2C19, was responsible for the production of several metabolites with hydroxylation at the indole moiety (M6, M7, and M8).
Supersomes are microsomes prepared from insect cells infected by baculovirus for coexpressing individual rh P450 isoenzymes plus rh P450 reductase and, therefore, have no interfering E. coli enzymes. Incubation with CYP3A4 Supersomes revealed M1 as the sole metabolite in 6% yield (Table 1) . In contrast to the whole-cell biotransformation with CYP3A4 in E. coli, no reduction of the hydroxamic acid group occurred. Incubation with CYP2D6 Supersomes showed M6 in 6% yield and M1 in 1% yield.
The P450 isoform CYP3A4 was selected for preparative synthesis of metabolites, because the oxidative metabolism of LBH589 in humans is mainly mediated by this P450 (S. Clive, M. M. Woo, M. Stewart, T. Nydam, L. Kelly, P. Squier, and M. Kagan, manuscript in preparation). Whole-cell biotransformation with CYP3A4 and subsequent purification yielded metabolites M1 and M2 in 5-to 12-mg quantities.
In addition, CYP2D6 was selected for the remaining hydroxyl metabolites not covered by CYP3A4, and this experiment gave M4 (268 mg) and M7 (22 mg). The minimal threshold for isolation of metabolites from biotransformations in the scale applied (200 mg) is approximately 5% conversion. Therefore, it was not possible to isolate some minor metabolites. The isolated metabolites were compared with panobinostat for enzymatic HDAC activity, and the results were compiled in Table 5 .
Structure Elucidation. The structures of the metabolites M1, M2, M4, M7, and M8 were elucidated on the basis of different homonuclear and heteronuclear 2D spectra (Tables 2 and 3 ) and HR-MS results (Table 4 ). The MS/MS fragmentation of the other, not isolated, metabolites were analog either to the parent compound panobinostat or to M1 (Table 4 ) and allowed to propose structures for metabolites M3 and M6. Compound M5 was identified by comparison with synthetic standard.
Structure of M4. The compound M4 had one oxygen less than panobinostat according to HR-MS. This had to be the oxygen of the hydroxamic acid, because the molecule had only two oxygens and because the 13 C chemical shift Structure of M2. HR-MS revealed the same elemental composition as the parent compound panobinostat. The 13 C-and 1 H-NMR data of the cinnamic amide part were virtually identical to M4. The aromatic protons in positions 4 to 7, and the methyl group showed a high field shift because of the reduction of the parent indole ring into an indoline-type ring system. Moreover, the geminal CH 2 protons of C-11, C-12, and C-14 were split, because they possessed adjacent chiral centers. The structure of M2 was supported by 1 H, COSY, HSQC, and HMBC experiments (Fig. 1) .
Structure of M1. The metabolite M1 had one oxygen more than M2. The 1 H-NMR spectral data of the two compounds were very similar, with the exception of the missing amide N-H signals and an additional OH signal at 5.28 ppm. These findings left only the amide nitrogen as an attachment point of this oxygen, leading to the hydroxamic acid analog of M2. Therefore, this moiety remained unchanged from the parent compound panobinostat.
Structure of M8. The compound M8 had one oxygen more than M2 according to HR-MS. The 13 C-and 1 H-NMR data were identical except for the aromatic ring at the left part of the molecule, suggesting a hydroxylation. This aromatic hydroxylation was deduced by 1 H and 13 C shifts of the aromatic protons and carbons. An oxidation at C-5 or C-6 would have provided the same aromatic coupling pattern, but the 1 H and 13 C shifts were in accordance only with an H-6 substitution. Homonuclear and heteronuclear 2D spectra supported unambiguously the determined tricyclic structure (Fig. 1) . Because the 3-OH proton was very broad, a nuclear Overhauser effect could not be seen to CH 3 -10. The relative stereochemistry at C-2 and C-3 had to be cis, because a trans-connection of the two five-membered rings could be excluded because of the enhanced rigidity of the indoline ring by its endocyclic aromatic bond. In conclusion, there was no evidence seen in the NMR spectra for the entropically unfavorable trans-isomer.
Structure of M7. The compound M7 had one oxygen more than M4 according to HR-MS, and the two metabolites had very similar 1 H-NMR spectra, with the exception of the indole ring. The similar coupling pattern of that moiety to the one of M8 and the chemical shifts suggested a hydroxylation at carbon-6.
Discussion
The product ion spectrum of M1 is displayed in Fig. 2 . The dominant ion at m/z 144.1 had an elemental composition of [C 10 H 10 N] ϩ and was presumably formed by a rearrangement (see Fig. 4 ). The rearrangement of indole derivatives to form very stable protonated quinoline ions has been reported with electron ionization and CID fragmentation (Stagno d'Alcontres et al., 1973; Prokai et al., 1993) . The analogous ion to m/z 144.1 was also formed in fragmentation of 6 in low intensity (Ronsein et al., 2009) . Therefore, the ring that had been closed during CYP3A4 metabolism reopened in CID fragmentation, so that a simple interpretation of the fragmentation pattern might have lead to erroneous metabolite structures. Notably, the fragment m/z 144 of M1 corresponded formally to a loss of CH 2 compared with m/z 158 of panobinostat, suggesting, wrongly, that hydroxylation at carbon-11 might have occurred. The proposed fragmentation mechanism was supported by HR-MS on an orbitrap and in MS 3 experiments. The fragmentation of the parent compound panobinostat (Fig. 3) showed two characteristic fragments: m/z 158, where cleavage of the bond 12-13 next to the secondary amino group had occurred, and m/z 176, as in Fig. 4 .
The proposed mechanism of formation of the metabolites is shown in Scheme 1. Epoxidation might be the first step catalyzed by CYP3A4 and other P450 enzymes. This epoxide, in turn, reacts via an FIG. 5 . Ring-forming metabolism and the natural product brevianamide E (13). (Prince et al., 2009) . The biological activity of the isolated metabolites was compared with panobinostat (Atadja 2009 ) for enzymatic HDAC activity (Table 5) : metabolite M4, where the zinc-binding hydroxamic acid had been reduced to an amide, was virtually inactive in all the tested HDACs. M2 and M7 inhibited HDACs in the low micromolar range. Such minor inhibition might be due to small unknown impurities in the isolated compounds. The inhibitory activity of M1 for HDAC8 and the class II enzymes HDAC4 and HDAC6 was in a similar range to panobinostat. Class III HDACs were not tested.
A cyclic melatonin metabolite 3 (Fig. 5 ) with a very similar tricyclic structure to M1 was proposed by Tan et al. (1998) based on 2D COSY 1 H-NMR studies. Later, Agozzino et al. (2003) showed that this structure was not correct, because it was not compatible with the 13 C-NMR and that the metabolite had structure 4. Chemical oxidation of tryptophan to the tricyclic product 6 can be achieved by various methods, including oxidation with peroxoacetic acid (Savige W 1975) , by photooxidation followed by reduction (Nakagawa et al., 1981) , by horseradish peroxidase (Nguyen et al., 1986a) , or electrochemically (Nguyen et al., 1986b) , and its 13 C-NMR has been described (Yang et al., 2003) . Furthermore, the tricyclic moiety is quite common in natural products, e.g., brevianamide E (13), which belongs, together with the paraherquamides, to an unusual class of prenylated indole-derived alkaloids produced by Penicillium sp. and Aspergillus sp. (Williams, 2002) .
Cyclized metabolites are quite rarely described. An example is the anti-inflammatory drug indomethacin 7 (Fig. 5) , where an intramolecular lactonized product is formed upon incubation with rat microsomes and an 2,3-epoxide is proposed as an intermediate in vitro (Komuro et al., 1996; Li et al., 2005) . The oxidative ring closure of the estrogen receptor modulator 9 proceeds in a CYP3A4-mediated reaction (Zhang et al., 2005) , presumably via a radical coupling. Also, for the major human metabolite 12 of the 5-hydroxytryptamine 1B receptor antagonist elzasonan 11, a radical mechanism of formation is proposed (Kamel et al., 2010) . Other examples of cyclized metabolites are aminals, where the cyclized metabolite is formed from an aldehyde intermediate. A recent example is the inhibitor of the human epidermal growth factor BMS-690514 14, where a substituted pyrrolo[2,1-f][1,2,4]triazine ring is opened and the aldehyde formed binds to a different, more nucleophilic, nitrogen in the molecule with ring closure (Hong et al., 2011) .
In conclusion, the isolation of five panobinostat metabolites produced under catalysis of rh CYP3A4 and CYP2D6 allowed us to establish their unusual and unexpected structures. The amount isolated was sufficient not only to elucidate the structure unambiguously, but also to investigate their biological activity in vitro. Furthermore, they were provided as reference material to clarify animal or human metabolism in vivo. The metabolite M2 corresponded to the one that had a prolonged T max in rat plasma, as mentioned in the Introduction. The human metabolic pathways of panobinostat have been established recently (S. Clive, M. M. Woo, M. Stewart, T. Nydam, L. Kelly, P. Squier, and M. Kagan, manuscript in preparation). It is very complex with approximately 80 distinct metabolites that include oxidation of the methyl indole ring, as described in this publication, a number of distinct glucuronidations, and multiple biotransformations of the hydroxamic acid-containing side chain, some of which were not observed in this study. These multiple pathways occurring alone and in multiple combinations lead to the observed complexity. Knowledge of the soft spot of metabolism contributed to the design of novel deacetylase inhibitors with improved metabolic properties and no doselimiting cardiac effects (Shultz et al., 2011) .
